Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation

To improve prognosis of post-transplant lymphoproliferative disease (PTLD), a sequential therapeutic strategy that rituximab-based treatments followed by donor lymphocyte infusion (DLI) or autologous EBV-specific cytotoxic T lymphocytes (EBV-CTL) for biopsy-proven EBV-associated PTLD in recipients o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Jiang, Xinmiao, Xu, Lanping, Zhang, Yu, Huang, Fen, Liu, Daihong, Sun, Jin, Song, Chaoyang, Liang, Xinquan, Fan, Zhiping, Zhou, Hongsheng, Dai, Min, Liu, Can, Jiang, Qianli, Xu, Na, Xuan, Li, Wu, Meiqing, Huang, Xiaojun, Liu, Qifa
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910706/
https://ncbi.nlm.nih.gov/pubmed/27467959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1139274
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky